Lead Product(s) : Teicoplanin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Inhaled Teicoplanin Completed Phase 1 Clinical Trial in Cystic Fibrosis
Details : Neupharma is developing an inhaled formulation of teicoplanin, a glycopeptide antibiotic, for the treatment of methicillin-resistant Staphylococcus aureus infections in patients with cystic fibrosis.
Product Name : Teicoplanin Sandoz
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 18, 2021
Lead Product(s) : Teicoplanin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CORVax12
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : OncoSec Immunotherapies
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : U.S. Food and Drug Administration (FDA) has cleared the Cliniporator platform for use in the upcoming Phase 1 trial to be held at Providence Health investigating CORVax12, the Company's DNA-encodable vaccine candidate for COVID-19.
Product Name : CORVax12
Product Type : Vaccine
Upfront Cash : Undisclosed
November 24, 2020
Lead Product(s) : CORVax12
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : OncoSec Immunotherapies
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : ChAdOx1
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : The Jenner Institute, Oxford University
Deal Size : Undisclosed
Deal Type : Agreement
The Jenner Institute signs an agreement with Advent to develop a novel coronavirus vaccine
Details : The Jenner Institute at the University of Oxford has agreed a contract with Advent Srl, to produce the first batch of the novel coronavirus vaccine ChAdOx1 nCoV-19 for clinical testing.
Product Name : ChAdOx1
Product Type : Vaccine
Upfront Cash : Undisclosed
November 02, 2020
Lead Product(s) : ChAdOx1
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : The Jenner Institute, Oxford University
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Teicoplanin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
The Food and Drug Administration granted Teicoplanin the PEDIATRIC Orphan Drug Designation
Details : Neupharma is developing an inhaled formulation of teicoplanin, a glycopeptide antibiotic, for the treatment of methicillin-resistant Staphylococcus aureus infections in patients with cystic fibrosis.
Product Name : Teicoplanin Sandoz
Product Type : Antibiotic
Upfront Cash : Inapplicable
September 28, 2020
Lead Product(s) : Teicoplanin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GRAd-COV2
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Phase 1 clinical trial is evaluating the safety and immunogenicity of GRAd-COV2 in 90 healthy volunteers with an objective to select a vaccine dose for further investigation in a Phase 2/3 trial.
Product Name : GRAd-COV2
Product Type : Vaccine
Upfront Cash : Inapplicable
August 24, 2020
Lead Product(s) : GRAd-COV2
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable